1.Heart-Lung Transplantation in Korea.
Kook Yang PARK ; Doo Yun LEE ; Joon Ryang RHO
Yonsei Medical Journal 2004;45(6):1191-1197
Heart-lung transplantation is an effective treatment for patients with various forms of congenital heart disease or pulmonary hypertension. Since the first heart-lung transplantation in 1997, five transplants have been performed in Korea. Three cases were performed in 1997, one in 1998, and the latest one in 2002. The preoperative diagnoses were complex congenital heart disease (CHD) in 2, and CHD with Eisenmenger's syndrome in 3. In this paper, we report five cases of heart-lung transplantation performed in Korea, and include a review of the relevant literature.
Adult
;
Child
;
Ductus Arteriosus, Patent/complications
;
Eisenmenger Complex/etiology/*surgery
;
Female
;
Heart Defects, Congenital/complications/*surgery
;
Heart Septal Defects, Ventricular/complications/surgery
;
*Heart-Lung Transplantation
;
Humans
;
Korea
;
Male
;
Pulmonary Atresia/complications/surgery
2.8.5 year-follow-up of combined heart-lung transplantation in a patient.
Baopeng SHANG ; Jianguo HU ; Xinmin ZHOU ; Wei ZHANG ; Xiaobo LIAO ; Jianming LI
Journal of Central South University(Medical Sciences) 2013;38(2):212-215
To summarize the case of combined heart-lung transplantation for a patient who survived for 8.5 years. On September 20, 2003, at Second Xiangya Hospital of Central South University, homologous heartlung transplantation was performed on a male patient who was diagnosed with cardiopulmonary failure secondary to congenital ventricular septal defect with severe pulmonary hypertension. Heart-lung allograft was preserved with 1500 mL modified St.Thomas solution and 3000 mL modified LPD solution. Postoperative immunosuppressive therapies included: methylprednisolone and human anti-lymphocyte globulin protein in the induction period; and combination of ciclosporin A, CellCept and prednisolone in the stable period. In 2007, the treatment was changed to CellCept mg, twice a day+FK506 4 mg, twice a day. The patient lived 8.5 years of normal life with cardiac function of NYHA I-II. Echocardiogram showed left ventricular ejection fraction of 61% to 74%. Heart-lung transplantation proved reliable therapy modality for terminal cardiopulmonary failure. Excellent donor organ preservation and proper perioperative treatment are key factors for long-term survival after heart-lung transplantation.
Eisenmenger Complex
;
surgery
;
Follow-Up Studies
;
Graft Rejection
;
Heart Septal Defects, Ventricular
;
complications
;
surgery
;
Heart-Lung Transplantation
;
methods
;
Humans
;
Hypertension, Pulmonary
;
etiology
;
surgery
;
Immunosuppressive Agents
;
therapeutic use
;
Male
;
Young Adult